

EPCORE™ DLBCL-2

M20-621

Don't face the journey with lymphoma *alone.*

The journey with lymphoma shouldn't be a lonely one—if you have been recently diagnosed with diffuse large B-cell lymphoma (DLBCL), join a growing community of people seeking answers through clinical research. Consider participating in the EPCORE DLBCL-2 clinical research study.

The EPCORE DLBCL-2 Clinical Research Study

The EPCORE DLBCL-2 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with newly diagnosed DLBCL.

You may be able to take part in the EPCORE DLBCL-2 Study if you:

- Are 18 to 79 years old
- Have been diagnosed with DLBCL
- Have not received any prior therapy to treat your DLBCL

If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you.

This investigational drug being studied in patients with DLBCL is under clinical development and is not approved for use by regulatory health authorities. Safety and efficacy are under evaluation.

FAQs

What's involved with participation in the EPCORE DLBCL-2 Study?

During the study, participants will either receive the investigational drug in combination with standard-of-care drugs or standard-of-care drugs alone.

- The study duration will vary from person to person depending on their response to their assigned study drugs.
- There are up to 8 study treatment cycles. Each cycle will last 21 days.
 - Participants and the study staff will know which study drugs are being given. There is no placebo in this study.
- The investigational drug will be given as a subcutaneous injection (under the skin). The standard-of-care drugs include both immunotherapy and chemotherapy. They will be given through an intravenous injection (delivered through a tiny tube into the vein) and as a capsule or tablet taken by mouth.
- Participants may leave the study at any time without further explanation.

Does participating in this study cost anything?

If you qualify for and agree to participate in the study, you will not have to pay for the investigational drug. In addition, reimbursement for study-related travel expenses may be available.

If prequalified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

- **Ask any important questions you may have.** These can be any questions you may have about this study or clinical research in general.
- **Determine if the EPCORE DLBCL-2 Study may be right for you.** You will speak with a study coordinator and learn more about the study. The study coordinator will ask you about your health history to determine if you are eligible for the study. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for study participation. You can also leave the study at any time. Once you have signed the study consent form, the research staff will perform a series of tests to determine if you are right for the study, and if the study is right for you.

What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience a worsening of your disease at any time during the study, please let the study doctor and staff know.

Where are the study clinics located?

There are study clinics located throughout the world. Find a location near you at:

[EPCORE-trials.com/locations](https://www.epcore-trials.com/locations).